Frederick, Maryland (PRWEB) November 25, 2014

American Spine is a practice on the cutting edge, committed to providing the latest, most effective, and innovative treatments for its patients. As part of this philosophy, American Spine joins the excitement surrounding Regenerative Medicine, a modern and progressive field of orthopedics and sports medicine. Regenerative Medicine involves the application of biological therapy treatments that enhance the body's ability to heal itself.

Dr. Sandeep Sherlekar, M.D., an owner and physician at American Spine, comments: "PRP and Stem Cell Treatments are revolutionary regeneration options for now and the future."

The major benefit of PRP and Stem Cell Therapy Treatments is the use of the patient's own whole blood, bone marrow stem cells and adipose stem cells, thus eliminating the risk of rejection or infection from other donors. These treatments are increasing in popularity as an alternative to other more invasive techniques in treating ailments such as: Muscle Tears, Meniscus and ACL Injuries, Tennis and Golf Elbow, Patellofemoral Pain Syndrome, various types of Tendonitis, Plantar Fasciitis, Spine Disease with either Degenerative Disks or Annular Tearing, Osteoarthritis in the joints and many more. They are used as a way to speed healing after other methods of treatment or to aid in the healing of resistant, long lasting injuries.

The blood and/or stem cells are harvested from the patient and are then prepared using state-of-the-art technologies. The preparation of PRP allows for a platelet sample that is 5 times more concentrated with platelets than normal blood. Similarly, the preparation of the patient's stem cells produces a much higher concentration of stem cells, both of which are essential in the healing process. The PRP and/or stem cells are then injected back into the patient's injured or degenerated tissues under guided imaging. The potential complications of such treatments are similar to those associated with regular joint injections.

American Spine stringently follows the FDA guidelines for the clinical use of blood and stem cells. We do not expand, reproduce or grow anything within a culture.

If you are interested in learning more about these treatments as a method to your own healing process or that of your patients, please visit the following link: http://www.americanspinemd.com/blog/platelet-rich-plasma-prp-and-autologous-stem-cell-treatment or call our offices to request additional information about these revolutionary therapies. We are offering a free consultation for new patients who are considering these treatments. The individual patient's treatment protocol will be formulated and discussed during the consultation.

At American Spine, our multidisciplinary team of physicians treat each patient's individual needs. Using the latest techniques and state-of-the-art equipment to diagnose pain, our practitioners determine a plan to meet each patient's unique diagnosis. We have assembled the very best team of healthcare professionals who can most effectively help our patients with a compassionate and personalized approach. We have 10 Maryland locations and one location in Gettysburg, PA to service your individual needs.

Contact Information: American Spine 1050 Key Parkway, Suite 104, Frederick, MD 21702 ph: 240-629-3939 http://www.americanspinemd.com

###

Here is the original post:

American Spine Launches Plasma Rich Platelet Therapy and Stem Cell Therapy Treatments

CINCINNATI -- The daughter of a Cincinnati Bengal who has already been through a lot spent another day in the hospital for treatment Tuesday.

Leah Still -- Devon Stills daughter -- underwent a stem cell transplant procedure at Children's Hospital of Philadelphia. The stem cell treatment is an effort to regenerate her bone marrow and stem cells.

Stem cells definitely smell like corn...yall wasn't lying

Still flew to Philadelphia Monday to be with Leah. They went shopping at a mall.

The smile you have after shutting down the mall, literally. This girl had security and the... http://t.co/HHWtLhf4pf pic.twitter.com/QFRMJsdlCX

Still tweeted another photo Tuesday while they waited for her treatment to begin.

Selfies in the hospital to pass time by as we wait for the stem cells http://t.co/q6JZOIyi9q pic.twitter.com/ogB0J0Gitg

Leah was diagnosed with stage 4 neuroblastoma in June. She had surgery to remove a tumor from her abdomen in September, followed by chemotherapy to try to remove the cancer from her bone marrow.

She has already been treated with a round of chemotherapy and radiation.

Still said the family hopes that will be her only round of chemo and radiation but that it depends on how her results come back. He said it will take four to six weeks to determine if more treatments are necessary.

Link:

Leah Still to undergo stem cell therapy

Dallas, TX -- (ReleaseWire) -- 11/24/2014 -- The report Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020 analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Asia-Pacific, Europe, and the Rest of the World (RoW).

Browse 57 market data tables 32 figures spread through 196 Slides and in-depth TOC on Stem Cell Therapy Market http://www.marketsandmarkets.com/Market-Reports/stem-cell-technologies-and-global-market-48.html

Early buyers will receive 10% customization on this report.

The global stem cell therapy market is expected to reach $330 million by 2020, at a CAGR of 39.5% from 2015 to 2020. The global market on the basis of the mode of treatment is segmented into allogeneic and autologous stem cell therapy. The allogeneic stem cell therapy is expected to command the largest share of the market in 2015, and is also expected to grow at a higher CAGR than autologous therapies from 2015 to 2020. Based on the therapeutic applications, the global market is segmented into eye diseases, metabolic diseases, GIT diseases, musculoskeletal disorders, immune system diseases, CNS diseases, CVS diseases, wounds and injuries, and others.

Get PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=48

Based on geography, the market is divided into North America, Asia-Pacific, Europe, and the Rest of the World (RoW). In 2015, North America is expected to hold the largest share in the global market, followed by Asia-Pacific, Europe, and the RoW (Rest of the World). The Asia-Pacific region is estimated to grow at the highest CAGR in the forecast period, owing to factors such as presence of huge patient population base, increasing regulatory support through favorable government policies, strong product pipelines of stem cell therapies, and rising licensing activities.

Inquiry Before Buying: http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=48

Major players such as Mesoblast Ltd. (Australia), Aastrom Biosciences Inc. (U.S.), Celgene Corporation (U.S.), and StemCells, Inc.(U.S.) are adopting several growth strategies such as new product approvals, partnerships, agreements, collaborations, joint ventures, mergers, and acquisitions in order to keep pace with the evolving industry trends.

Browse related reports: Cell Analysis Market by Instruments (Flow Cytometer, Microscope, Microfluidics, QPCR), Consumables, Application (Cell Identification, Cell Viability, Cell Proliferation, Cytology, Signal Transduction, Single Cell Analysis) - Global Forecast to 2018

http://www.marketsandmarkets.com/Market-Reports/cell-analysis-market-157543946.html

Read more from the original source:

Stem Cell Therapy Market Poised to Reach $330 Million in ...

Contact Information

Available for logged-in reporters only

Newswise In a study led by Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research member, Dr. John Chute, UCLA scientists have for the first time identified a unique protein that plays a key role in regulating blood stem cell replication in humans.

This discovery lays the groundwork for a better understanding of how this protein controls blood stem cell growth and regeneration, and could lead to the development of more effective therapies for a wide range of blood diseases and cancers.

The study was published online November 21, 2014 ahead of print in the Journal of Clinical Investigation.

Hematopoietic stem cells (HSCs) are the blood-forming cells that have the remarkable capacity to both self-renew and give rise to all of the differentiated cells (fully developed cells) of the blood system. HSC transplantation provides curative therapy for thousands of patients annually. However, little is known about the process through which transplanted HSCs replicate following their arrival in human bone marrow. In this study, the authors showed that a cell surface protein called protein tyrosine phosphatase-sigma (PTP-sigma) regulates the critical process called engraftment, meaning how HSCs start to grow and make health blood cells after transplantation.

Mamle Quarmyne, a graduate student the lab of Dr. Chute and first author of the study, demonstrated that PTP-sigma is produced (expressed) on a high percentage of mouse and human HSCs. She showed further that genetic deletion of PTP-sigma in mice markedly increased the ability of HSCs to engraft in transplanted mice.

In a complementary study, she demonstrated that selection of human blood HSCs which did not express PTP-sigma led to a 15-fold increase in HSC engraftment in transplanted immune-deficient mice. Taken together, these studies showed that PTP-sigma suppresses normal HSC engraftment capacity and targeted blockade of PTP-sigma can substantially improve mouse and human HSC engraftment after transplantation.

Chute and colleagues showed further that PTP-sigma regulates HSC function by suppressing a protein, RAC1, which is known to promote HSC engraftment after transplantation.

These findings have tremendous therapeutic potential since we have identified a new receptor on HSCs, PTP-sigma, which can be specifically targeted as a means to potently increase the engraftment of transplanted HSCs in patients, said Chute, senior author of the study and UCLA Professor of Hematology/Oncology and Radiation Oncology. This approach can also potentially accelerate hematologic recovery in cancer patients receiving chemotherapy and/or radiation, which also suppress the blood and immune systems.

Read more:

UCLA Researchers Unlock Protein Key to Harnessing Regenerative Power of Blood Stem Cells

PUBLIC RELEASE DATE:

24-Nov-2014

Contact: Jen Middleton jen.middleton@ed.ac.uk 44-131-650-6514 University of Edinburgh @uniofedinburgh

Liver disease patients could be helped by a new cell therapy to treat the condition.

Researchers from the University of Edinburgh have received funding to start testing the therapy in patients within the next year.

It will be the world's first clinical trial of a new type of cell therapy to treat liver cirrhosis, a common disease where scar tissue forms in the organ as a result of long-term damage.

The Edinburgh team has received funding from the Medical Research Council and Innovate UK to investigate the disease, which claims 4000 lives in the UK each year.

The only successful treatment for end-stage liver cirrhosis at present is an organ transplant. The new therapy is based on a type of white blood cell called a macrophage, which is key to normal repair processes in the liver.

Macrophages reduce scar tissue and stimulate the liver's own stem cells to expand and form into healthy new liver cells.

Scientists will take cells from the blood of patients with liver cirrhosis and turn them into macrophages in the lab using chemical signals.

Read more:

Cell therapy trial offers new hope to liver disease patients

Stem Cell Therapy: Dr. Roberta Shapiro - A NY Physician #39;s Path to Panama
Special Guest Speaker, Roberta F. Shapiro DO, FAAPM R speaks about: A New York Doctor #39;s Path to Panama at the Stem Cell Institute #39;s Stem Cell Therapy Publi...

By: http://www.cellmedicine.com

See the original post here:

Stem Cell Therapy: Dr. Roberta Shapiro - A NY Physician's Path to Panama - Video

Buddy the beagle can walk again
Buddy the beagle wasn #39;t able to walk when he first arrived at the University of Minnesota Veterinary Medical Center. With the help of U of M veterinarians and staff, using stem-cell therapy,...

By: UMN Veterinary Medical Center

Go here to see the original:

Buddy the beagle can walk again - Video

Nov. 23, 2014, 3:05 p.m.

It is hoped that a trial due to start next year, and involving about 20 Australian children with cerebral palsy, will show the benefits of using stem cells from their own umbilical cord blood to treat the condition.

About 20 Australian children with cerebral palsy will be infused with their own umbilical cord blood in a trial due to start next year, as physicians warn families against travelling overseas for experimental stem cell treatments.

The long-awaited Australian trial will provide some of the world's first evidence about the safety and effectiveness of using stem cells from umbilical cord blood to repair brain injury that leads to cerebral palsy.

Researchers are waiting on ethics approval for the trial which will provide treatment to families who have chosen to store their child's cord blood at private banks.

In some cases, children with cerebral palsy will be able to receive a sibling's cord blood if this is available.

Cerebral Palsy Alliance head of research Iona Novak said the study, led by the Murdoch Childrens Research Institute, will recruit children from around Australia who have access to privately banked cord blood.

Children aged one to 10 will receive infusions at private blood banks in Melbourne, Sydney and Brisbane, and will be assessed before and after the treatment to check for improvements.

Researchers will be unable to access cord blood from a public bank, which collects blood to treat blood disorders such as leukaemia and cannot be used for untested new therapies.

Associate Professor Novak said the trial was an important first step towards establishing whether stem cells could help repair the brain injury that leads to cerebral palsy, a series of disabilities associated with movement and posture.

Read more here:

Stem cell trial to begin for children suffering from cerebral palsy

AVON LAKE, OH (WOIO) - When Shannon Goulding's bloodhound Butler tore a ligament in his knee his entire personality changed.

"He was sedentary, and he wasn't as active as before," said Goulding.

Dr. Petti a veterinarianat the Avon Lake Animal Clinic told Goulding, who also works at the clinic, suggested that stem cell therapy could help.

"Watching him walk he looked stiff and uncomfortable," said Petti.

The therapy was successful. Goulding said after four weeks after the surgery she could see a change the way Butler moved.

Stem cell therapy helps animals suffering from sore knees and joints by using their own fat cells.

"You take them from the patient, you process them, make them active, and then you re inject them into the parts of the animal that are giving them problems," said Petti.

Petti said Avon Lake Animal Clinic has helped about 15 animals with stem cell therapy and people from all over the country have been calling.

One injection of stem cells can last up to three years, and after that a second injection may be needed.

Stem cell therapy is also an expensive procedure. It ranges from $2,000-2,500, but for Goulding she says seeing Butler run free without pain is worth it.

The rest is here:

Local clinic treats animals with stem cell therapy

Researchers of CEU Cardenal Herrera University (CEU-UCH) for the first time transplanted bone marrow stem cells into damaged brain tissue while applying lipoic acid (a potent antioxidant), with the aim of improving neuroregeneration in the tissue. This new way of repairing brain damage, which combines cellular treatment with drug therapy, has shown positive results, especially in forming blood vessels (a process called angiogenesis) in damaged areas of the brains of adult laboratory mice. Angiogenesis is a process that is essential to the recovery of damaged neural tissues. The investigation was led by Jos Miguel Soria Lpez, deputy director of the Institute of Biomedical Sciences at CEU-UCH, and its results were published in the international medical journal Brain Injury.

Professor Soria, who is affiliated to the Department of Biomedical Sciences at CEU-UCH, heads the investigative group 'Strategies in Neuroprotection and Neuroreparation', which carried out the investigation in cooperation with the Andalusian Molecular Biology and Regenerative Medicine Centre (CABIMER), located in Sevilla, and the Mediterranean Ophthalmological Foundation, located in Valencia. The research team used the experience they obtained from their previous investigations on the neuroregenerative efficiency of lipoic acid to develop a new remediation strategy for patients of brain damage. This new therapy combines the transplantation of bone marrow stem cells into the brain -- in this case, the brains of adult rats -- with the administration of the potent antioxidant lipoic acid.

Lipoic acid is already used in the treatment of degenerative diseases such as multiple sclerosis or diabetic neuropathy. Professor Soria concluded from previous researches he conducted at CEU-UCH that it has the ability to increase the creation of blood vessels, which speeds up cerebral immune response after an injury and stimulates the restoration of damaged tissues. Several other researches, for their part, proved that after brain damage stem cell therapies using a patient's own bone marrow induce functional improvements. The two therapies -- one cellular; the other one pharmacological -- were both applied in this research so as to evaluate their combined effect.

New blood vessels

Angiogenesis -- the process that forms new blood vessels -- in the treated neuronal tissue began only eight days after the application of this new, combined therapy. CEU-UCH professor Soria says that "although bone marrow stem cells disappear from the brain tissue where they were transplanted after only 16 days, new cells keep forming. To put it another way, brain tissue is regenerated by new cells that appear in the brain as a result of stem cell transplantation. This proves the regenerative efficiency of the new combined therapy."

The research also shows how the blood vessels that formed after the treatment grow into the damaged area of the brain. "They act as a kind of scaffolding to that area that allows microglia cells to migrate," professor Soria says. "In the damaged area, they contribute to regeneration." He adds that "the application of both treatments results into high angiogenic activity, which is crucial for an efficient recovery of the damaged brain area." According to Soria, "the laboratory mice that recovered fastest from brain injuries were those that had a higher density of regenerated blood vessels."

Taking into consideration brain damage is, especially among children and adolescents, one of the leading causes of disability and death in the developed world, the good results that were obtained from the combination of the two therapies make the research team very hopeful. "Combining an antioxidant such as lipoic acid with bone marrow stem cells has proven to be an effective remedy," Soria observes. The team plans to conduct future research into similar combined therapies.

The image above shows the transplant of bone marrow stem cells from transgenic mice under the effects of cerebral cortex after suffering local brain damage. Also visible is a neuroprotective drug therapy.

Story Source:

The above story is based on materials provided by Asociacin RUVID. Note: Materials may be edited for content and length.

Excerpt from:

Brain injuries in mice treated using bone marrow stem cells, antioxidants

Elite Emage Stem Cell Therapy
Elite Emage Stem Cell Therapy.

By: Elite Emage

Read more from the original source:

Elite Emage Stem Cell Therapy - Video

Kilian Before After Stemlogix Stem Cell Therapy
dog with arthritis treated with autologous stem cells.

By: mark Greenberg

The rest is here:

Kilian Before & After Stemlogix Stem Cell Therapy - Video

Low back, neck, hip, shoulder, and knee arthritis 7 months after stem cell therapy by Adelson
Spence describes his outcome from his "full-body make-over" by Harry Adelson, N.D.. Seven months ago, Spence had his own bone marrow stem cells injected into his low back, neck, hips, shoulders,...

By: Harry Adelson, N.D.

Follow this link:

Low back, neck, hip, shoulder, and knee arthritis 7 months after stem cell therapy by Adelson - Video

PUBLIC RELEASE DATE:

19-Nov-2014

Contact: Lauren Woods lauren.woods@mountsinai.org 646-634-0869 The Mount Sinai Hospital / Mount Sinai School of Medicine @mountsinainyc

Delivering stem cell factor directly into damaged heart muscle after a heart attack may help repair and regenerate injured tissue, according to a study led by researchers from Icahn School of Medicine at Mount Sinai presented November 18 at the American Heart Association Scientific Sessions 2014 in Chicago, IL.

"Our discoveries offer insight into the power of stem cells to regenerate damaged muscle after a heart attack," says lead study author Kenneth Fish, PhD, Director of the Cardiology Laboratory for Translational Research, Cardiovascular Research Center, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai.

In the study, Mount Sinai researchers administered stem cell factor (SCF) by gene transfer shortly after inducing heart attacks in pre-clinical models directly into damaged heart tissue to test its regenerative repair response. A novel SCF gene transfer delivery system induced the recruitment and expansion of adult c-Kit positive (cKit+) cardiac stem cells to injury sites that reversed heart attack damage. In addition, the gene therapy improved cardiac function, decreased heart muscle cell death, increased regeneration of heart tissue blood vessels, and reduced the formation of heart tissue scarring.

"It is clear that the expression of the stem cell factor gene results in the generation of specific signals to neighboring cells in the damaged heart resulting in improved outcomes at the molecular, cellular, and organ level," says Roger J. Hajjar, MD, senior study author and Director of the Cardiovascular Research Center at Mount Sinai. "Thus, while still in the early stages of investigation, there is evidence that recruiting this small group of stem cells to the heart could be the basis of novel therapies for halting the clinical deterioration in patients with advanced heart failure."

cKit+ cells are a critical cardiac cytokine, or protein receptor, that bond to stem cell factors. They naturally increase after myocardial infarction and through cell proliferation are involved in cardiac repair.

According to researchers there has been a need for the development of interventional strategies for cardiomyopathy and preventing its progression to heart failure. Heart disease is the number one cause of death in the United States, with cardiomyopathy or an enlarged heart from heart attack or poor blood supply due to clogged arteries being the most common causes of the condition. In addition, cardiomyopathy causes a loss of cardiomyocyte cells that control heartbeat, and changes in heart shape, which lead to the heart's decreased pumping efficiency.

"Our study shows our SCF gene transfer strategy can mobilize a promising adult stem cell type to the damaged region of the heart to improve cardiac pumping function and reduce myocardial infarction sizes resulting in improved cardiac performance and potentially increase long-term survival and improve quality of life in patients at risk of progressing to heart failure," says Dr. Fish.

Originally posted here:

Delivering stem cells into heart muscle may enhance cardiac repair and reverse injury

Last year Vicki Pegalow, Buffalo, received bad news that she needed to have her left knee replaced. Having experienced total knee replacement of her right knee 14 years earlier, she was distressed about the anticipated surgery and the road to recovery she would be facing.

An online service is needed to view this article in its entirety. You need an online service to view this article in its entirety.

Or, use your linked account:

Need an account? Create one now.

Or, use your linked account:

kAm!682=@H 92AA6?65 E@ CF? :?E@ 2 7C:6?5 2E E96 8C@46CJ DE@C6 H9@ 925 72465 E96 D2>6 :DDF6 E96 J62C 367@C6] r2C@=J? !2EE6CD@?[ qF772=@[ H9@ 925 2=D@ DF776C65 49C@?:4 @C6 E92? 6G6CJE9:?8 D96 925 9@A65 7@C]k^Am

kAm%96 EC62E>6?E E92E !2EE6CD@? DA@<6 @7 H2D DE6>46== E96C2AJ :?;64E:@?D 😕 E96 5@?6 2D 2? @FEA2E:6?E 2E E96 @77:46 @7 x??@G2E:G6 $A@CED |65:4:?6 😕 $AC:?87:6=5]k^Am

kAm!682=@H H2D 4@?46C?65 E92E D96 >:89E ?@E 36 2? 6=:8:3=6 42?5:52E6 7@C E96 EC62E>6?E D:?46 )C2JD 2?5 |#xD @? 96C 6?:D4FD[ 2?5 D96 925 E2<6? 2 $J?G:D4 :?;64E:@? ?:?6 >@?E9D AC:@C] $96 =62C?65 E92E E96 $J?G:D4 H@F=5 ?@E 9:?56C @C 42FD6 25G6CD6 67764ED :7 D96 AC@466565 H:E9 E96 DE6>46== :?;64E:@?D]k^Am

kAm$J?G:D4 😀 2? :?;64E:@? E92E 4@?E2:?D 2 86==:<6 >:IEFC6 >256 7C@> 2 DF3DE2?46 42==65 9J2=FC@?2? E92E 4@>6D 7C@> 49:4<6? 4@>3D] xE DFAA=6>6?ED E96 7=F:5 😕 E96 @?E9D @7 @DE6@2CE9C:E:D 46== :?;64E:@?D ?@E @?=J C6=:6G6 A2:?[ 3FE 42? 96=A 962= E96 52>2865

kAm$E6>46== C6D62C49 92D 366? 2C@F?5 7@C @G6C 2 46?EFCJ[ 3FE :E 92D?E 366? F?E:= E96 =2DE 4@FA=6 @7 564256D E92E :E 92D 82:?65 D@ >F49 4@?EC@G6CD:2= AF3=:4:EJ] ~G6C E96 =2DE 76H J62CD[ ?2E:@?2= A@=:4:6D 2?5 5632E6 2>@?8 E96 AF3=:4 2D H6== 2D C6=:8:@FD 8C@FAD[ 8@G6C?>6?E @77:4:2=D 2?5 D4:6?E:DED 92G6 C6DF=E65 😕 G2C:@FD =2HD 4@?46C?:?8 DE6>46== 92CG6DE:?8 7@C C6D62C49 @C 5:D62D6 EC62E>6?E AFCA@D6D] %96 8@2=D @7 DF49 A@=:4:6D 2C6 E@ D2768F2C5 E96 AF3=:4 7C@> F?6E9:42= DE6>46== C6D62C49 2?5 FD6 H9:=6 DE:== DFAA@CE:?8 ?6H 56G6=@A>6?ED 2?5 25G2?46>6?ED 😕 E96 7:6=5]k^Am

Read the rest here:

Stem-cell therapy knee injections successful for women

By: Adam Feuerstein | 11/18/14 - 10:16 AM EST

Inject a cocktail of undifferentiated stem cellsinto a patient who has suffered a heart attack, and days or even weekslater, the stem cells transform into cardiac cells and rebuild the damaged heart muscle. Months later, the patient has a "new" healthy heart.It's a great story. But so far, the proof remains elusive though not for a lack of trying.

The latest company to fulfill this ambitious scenario is NeoStem (NBS) which presented disappointing (but not surprising) results from a small study of its proprietary cardiac stem-cell therapy NBS10 at the American Heart Association annual meeting Monday. NeoStem tried to put some positive spin on the bad news but shares are down 25% to $5.10.

NBS10, formerly known as AMR-001, is an autologous stem-cell therapy derived from a patient's own bone marrow. When injected back into patients following a heart attack, the stem cells are supposed torestore blood flow, rebuild damaged cardiac muscle and improve function.

Except in NeoStem's study, NBS10 fell short on two primary endpoints designed to assess the therapy's efficacy. The study used non-invasive imaging to assess blood flow through the heart, six months after a single infusion of NBS10 or a placebo. There was no difference between NBS and placebo, NeoStem said.

The study's other co-primary efficacy endpoint was a measurement of adverse cardiac "MACE" events --defined as cardiovascular death, a repeatheart attack, heart failure hospitalization and coronary revascularization. To date, 17% of patientstreated with NBS10 have suffered a MACE event compared to 19% of patients in the placebo arm -- a difference which was not statistically significant.

NeoStem said NBS10 therapy was safe relative to placebo and that no patients treated with the stem cells have died compared to three deaths in the placebo patients. But with only one year of follow up on a small number of patients, any claims about a mortality benefit are clinically meaningless.

Originally posted here:

NeoStem's Stem Cell Therapy Fails Mid-Stage Heart Attack Study

Researchers at the Cedars-Sinai Heart Institute have found that injections of cardiac stem cells might help reverse heart damage caused by Duchenne muscular dystrophy, potentially resulting in a longer life expectancy for patients with the chronic muscle-wasting disease.

The study results were presented today at a Breaking Basic Science presentation during the American Heart Association Scientific Sessions in Chicago. After laboratory mice with Duchenne muscular dystrophy were infused with cardiac stem cells, the mice showed steady, marked improvement in heart function and increased exercise capacity.

Duchenne muscular dystrophy, which affects 1 in 3,600 boys, is a neuromuscular disease caused by a shortage of a protein called dystrophin, leading to progressive muscle weakness. Most Duchenne patients lose their ability to walk by age 12. Average life expectancy is about 25. The cause of death often is heart failure because the dystrophin deficiency leads to cardiomyopathy, a weakness of the heart muscle that makes the heart less able to pump blood and maintain a regular rhythm.

"Most research into treatments for Duchenne muscular dystrophy patients has focused on the skeletal muscle aspects of the disease, but more often than not, the cause of death has been the heart failure that affects Duchenne patients," said Eduardo Marbn, MD, PhD, director of the Cedars-Sinai Heart Institute and study leader. "Currently, there is no treatment to address the loss of functional heart muscle in these patients."

During the past five years, the Cedars-Sinai Heart Institute has become a world leader in studying the use of stem cells to regenerate heart muscle in patients who have had heart attacks. In 2009, Marbn and his team completed the world's first procedure in which a patient's own heart tissue was used to grow specialized heart stem cells. The specialized cells were then injected back into the patient's heart in an effort to repair and regrow healthy muscle in a heart that had been injured by a heart attack. Results, published in The Lancet in 2012, showed that one year after receiving the experimental stem cell treatment, heart attack patients demonstrated a significant reduction in the size of the scar left on the heart muscle.

Earlier this year, Heart Institute researchers began a new study, called ALLSTAR, in which heart attack patients are being infused with allogeneic stem cells, which are derived from donor-quality hearts.

Recently, the Heart Institute opened the nation's first Regenerative Medicine Clinic, designed to match heart and vascular disease patients with appropriate stem cell clinical trials being conducted at Cedars-Sinai and other institutions.

"We are committed to thoroughly investigating whether stem cells could repair heart damage caused by Duchenne muscular dystrophy," Marbn said.

In the study, 78 lab mice were injected with cardiac stem cells. Over the next three months, the lab mice demonstrated improved pumping ability and exercise capacity in addition to a reduction in heart inflammation. The researchers also discovered that the stem cells work indirectly, by secreting tiny fat droplets called exosomes. The exosomes, when purified and administered alone, reproduce the key benefits of the cardiac stem cells.

Marbn said the procedure could be ready for testing in human clinical studies as soon as next year. The process to grow cardiac-derived stem cells was developed by Marbn when he was on the faculty of Johns Hopkins University. Johns Hopkins has filed for a patent on that intellectual property and has licensed it to Capricor, a company in which Cedars-Sinai and Marbn have a financial interest. Capricor is providing funds for the ALLSTAR clinical trial at Cedars-Sinai.

Read more from the original source:

Cardiac stem cell therapy may heal heart damage caused by Duchenne muscular dystrophy

NEW YORK (TheStreet) -- Shares ofNeoStem (NBS) plummeted 25.52% to $5.05 in late morning trading Tuesdayafter the biotech company announced poor results from a trial of its proprietary cardiac stem-cell therapy NBS10.

NBS10, which used to be called AMR-001, missed two primary endpoints in the study to test the therapy's efficacy.The stem-cell therapy comesfrom a patient's own bone marrow and is injected into patients after a heart attack. The stem cells are then supposed to help blood flow and build cardiac muscle.

NeoStem's trial used non-invasive imaging to monitor blood flow through the heart six months after a one dose of NBS10 or a placebo. The study showed no difference between NBS and placebo, NeoStem said.

Must Read:NeoStem's Stem Cell Therapy Fails Mid-Stage Heart Attack Study

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Jim Cramer's protg, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Continued here:

NeoStem (NBS) Stock Plummets Today on Disappointing Cardiac Stem-Cell Therapy Data

Stem Cell Therapy for Labrador Retriever with Ruptured Tendon
Marc Smith DVM of Natchez Trace Veterinary Services and Pet-Tao Pet Foods explains how he utilizes VetraGenics Stem Cell Therapy to regenerate tissue and heal the tendon.

By: Marc Smith

More:

Stem Cell Therapy for Labrador Retriever with Ruptured Tendon - Video

A large-scale trial conducted in India has shown that stem cell therapy does not work in stroke patientsREUTERS

A study conducted on 120 patients in India has shown that stem cell treatment is not effective in treating paralysis resulting from a stroke.

The research which is thefirst large-scale study conducted in Indiacompared outcomes in those treated with stem cells to others and found no difference, reports Down to Earth.

While 60 patients with some form of disability of limbs caused by a stroke were given conventional treatment, an equal number received bone marrow stem cells in addition. All had experienced a stroke 3-4 weeks before the trial.

"We found that at the end of the first month, patients with stem cells showed more improvement compared to the control group. But at the end of the third month and one year, there was no difference," said Kameshwar Prasad, head, Department of Neurology, All India Institute of Medical Sciences (AIIMS), who led the study.

On an average 280 million bone marrow cells were injected, of which blood forming stem cells were around 2.9 million per patient.

The average age of patients in the study was around 50.

The study, published in the current issue of American journal Stroke, was conducted at AIIMS in New Delhi and four other hospitals covering four cities.

The study comes when many others have been suggesting that stem cells could help treat paralysis in stroke patients. The earlier study was done on a small number of patients as compared to the AIIMs study.

More research needs to be done, before stem cells are used in therapy as in India, many private clinics are openly offering stem cell treatment for various diseases.

Go here to read the rest:

Stem Cells Treatment Not Useful In Stroke Patients Finds Indian Study